KPV in nanoparticles: targeted delivery in colitis models
Evidence level: Cell and animal research with a specialized delivery system · Publication year: 2017
This overview discusses one original scientific publication on KPV. The source is included in PubMed, the literature database of the U.S. National Library of Medicine.
What was studied?
KPV was incorporated into hyaluronic acid-functionalized nanoparticles. The research focused on delivery to inflamed intestinal tissue and relevant cell types in preclinical models.
What did the researchers find?
The formulation studied promoted targeted delivery and reduced colitis-related outcomes in the mouse model used. The system combined peptide and carrier technology.
What are the limitations?
The results apply to the specific nanoparticle formulation. They do not prove comparable effects of free KPV, another route of administration, or a commercial vial in humans.
Significance for research
The study shows why delivery systems are an essential part of peptide research.
Official source
Original publication via PubMed — PMID 28143741
Research Use Only. This literature summary contains no treatment or usage advice. Research on a molecule is not evidence of the efficacy, safety, or purity of a Peptidera product. PubMed indexing is not product approval.
Related research products
View product specifications and available batch documentation. The studies discussed were not conducted with Peptidera products and do not prove the efficacy of our products. For laboratory research only; not for human or animal consumption.